TANILONE (Aspen Pharmacare Australia Pty Ltd)

Product name

TANILONE

Date registered

29 November 2022

Evaluation commenced

30 November 2021

Decision date

25 November 2022

Approval time

125 (255 working days)

Active ingredients

Methylprednisolone aceponate

Registration type

New generic medicine

Indication

TANILONE fatty ointment is indicated for the topical treatment of eczema and psoriasis in adults and children.

Registration process

First generic

First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine